Company to Provide Overview of Business Model and Expected Revenue Acceleration in Fiscal Year 2025 EDEN PRAIRIE, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today a change to its Virtual Investor Webinar date due to U.S. equity markets being closed for the National Day of Mourni ...

Business Model and Revenue Projections - The company will hold a virtual roadshow webinar to discuss its business operations and recent updates, including an overview of its business model and recent milestone achievements [1][2] - The company recently expanded its exclusive distribution agreement with Zimmer Biomet, one of the world's largest medical device manufacturers [2] - Product revenue grew by 77% to $3.5 million in fiscal year 2024, and is expected to increase to between $8 and $10 million in fiscal year 2025, representing a growth of 132% to 190% [2] Webinar Details - The webinar will include a presentation followed by a Q&A session, accessible via webcast or dial-in numbers [3] - The webinar is scheduled for Thursday, January 9, 2025, at 11:00 a.m. Eastern Standard Time [3] - A playback of the call will be available through January 23, 2025 [4] Company Overview - NeuroOne Medical Technologies Corporation is focused on developing minimally invasive and hi-definition solutions for EEG recording, brain stimulation, and ablation for patients with neurological disorders such as epilepsy, Parkinson's disease, and chronic pain [5] - The company is also exploring applications in other areas including depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence [5] Forward-Looking Statements - The press release contains forward-looking statements regarding the company's future performance, including expectations for significant product revenue growth and margin expansion in fiscal year 2025 [6] - These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially [6][7]

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q4 2024 Earnings Conference Call December 17, 2024 9:00 AM ET Company Participants Dave Rosa - Chief Executive Officer Ron McClurg - Chief Financial Officer Conference Call Participants Operator Good day, ladies and gentlemen. Welcome to the NeuroOne Fourth Quarter and Fiscal Year-End 2024 Earnings Call. Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa; and Ron McClurg, the company's Chief Financial Officer; Chris Volk ...

Exhibit 99.1 NeuroOne® Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025 Company's Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly EDEN PRAIRIE, Minn., December 17, 2024 -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transfo ...

Company's Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly EDEN PRAIRIE, Minn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the fourth quarter and fiscal year ended September 30, 2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) | --- | |-------- ...

License Provides Exclusive Commercialization Rights for US Distribution and Certain OUS MarketsAgreement expected to boost NeuroOne sales revenue and profitability EDEN PRAIRIE, Minn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the execution of an amendment to its existing distri ...

NeuroOne® Medical Technologies to Present at the 2024 ThinkEquity Conference EDEN PRAIRIE, Minn., October 24, 2024 – PRISM MediaWire – NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkE ...

NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX), a leading private markets solutions provider, today announced Enhanced Community Development, a part of P10 subsidiary Enhanced Capital Group LLC, was awarded a $65 million allocation from the New Markets Tax Credits (NMTC) program administered by the U.S. Treasury Department's Community Development Financial Institutions Fund. Under the program, the U.S. Treasury Department allocated a total of $5 billion to 104 Community Development Entitie ...

Forty-four ablations performed successfully in one patient Patient currently reportedly seizure free with improvements in mood and memory EDEN PRAIRIE, Minn., Sept. 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the OneRF Ablation System was recently used in a breakthrough patient pr ...